Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1264
Shown on this page
12
Current sort
Recently updated
Campus scope
UT Southwestern Medical Center, Dallas, TX
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UT Southwestern Medical Center, Dallas, TX. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 877–888 of 1,264 matching trials with a site at UT Southwestern Medical Center, Dallas, TX.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536
Site status not listed — check the official record
View directory record Official record
Conditions
Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Nemtabrutinib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting Phase 3 Interventional

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325
Site status not listed — check the official record
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting Phase 3 Interventional

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

NCT04333576
Site status not listed — check the official record
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix, Placebo, Combined Oral Contraceptive
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
176
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Extreme Lipids Repository

NCT04156997
Site status not listed — check the official record
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
No intervention is involved in this study
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Patients With and Without Phonotrauma

NCT05625191
Status at this site: Recruiting
View directory record Official record
Conditions
Phonotrauma
Interventions
Acoustic voice analysis, High-speed videoendoscopy
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
Status at this site: Recruiting
View directory record Official record
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Not applicable Interventional

Deep Brain Stimulation for Psychosis

NCT06257056
Status at this site: Recruiting
View directory record Official record
Conditions
Treatment-Refractory Schizophrenia
Interventions
Abbott Laboratories Infinity™ implantable deep brain stimulation system
Device
Lead sponsor
Bradley Lega
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting Not applicable Interventional

The BEAR III Trial for Bridge-Enhanced ACL (Anterior Cruciate Ligament) Restoration

NCT03348995
Site status not listed — check the official record
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture
Interventions
Bridge-Enhanced ACL Restoration (BEAR)
Device
Lead sponsor
Miach Orthopaedics
Industry
Eligibility
12 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
11
States / cities
San Diego, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting Phase 3 Interventional Results available

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02785952
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1201
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting Phase 3 Interventional

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

NCT05037123
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Postsurgical Pain
Interventions
Continuous ketamine infusion, Ketamine + Saline, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease

NCT04583878
Site status not listed — check the official record
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Blood draw (Visit 1), Blood draw (Visits 2 and 3)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Not applicable Interventional

MINT Conditioning to Improve Gait

NCT07041775
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Stroke, Stroke Gait Rehabilitation
Interventions
myoelectric interface for neurorehabilitation (MINT) conditioning, One muscle myoelectric feedback
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 9, 2026, 1:37 PM EST

About this UT Southwestern Medical Center institution page

What this page lists
ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.